# DRMA (Dermata Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Dermata Therapeutics, Inc. reported $6.64M in total assets and a net loss of $9.50M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/DRMA
- Markdown: https://convexityos.com/fundamentals/DRMA.md
- SEC CIK: 0001853816
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:10 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001853816&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$9.70M | Operating profit |
| Net Income | FY 2025 | -$9.50M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$1.86 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $4.82M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $2.93M | $8.20M | $4.07M | $5.65M | $3.46M | $1.61M |
| Selling, General & Admin | $4.84M | $4.31M | -- | -- | -- | -- |
| Total Operating Expenses | $7.77M | $12.51M | $8.04M | $9.67M | -- | -- |
| **Operating Income** | -$7.77M | -$12.51M | -$8.04M | -$9.67M | -$7.86M | -$3.17M |
| **EBITDA** | -- | -- | -- | -- | -$7.86M | -$3.17M |
| Interest Income | $215K | $226K | $247K | $64K | -- | -- |
| Interest Expense | -- | -- | -- | -- | $46K | $197K |
| Income Tax Expense | -- | $0 | $0 | $0 | $0 | $0 |
| **Net Income** | -$7.56M | -$12.29M | -$7.79M | -$9.61M | -$7.90M | -$3.24M |
| Basic EPS | -$8.16 | -$80.32 | -$399.90 | -$139.20 | -$24.30 | -$16.90 |
| **Diluted EPS** | -$8.16 | -$80.32 | -$399.90 | -- | -- | -- |
| Basic Shares Outstanding | 926.2K | 153.0K | -- | -- | 430.2K | 191.1K |
| Diluted Shares Outstanding | 926.2K | 153.0K | 19.5K | -- | -- | -- |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Revenue** | $74K | -- | -- | -- | -- | -- | -- | -- |
| Cost of Revenue | $34K | -- | -- | -- | -- | -- | -- | -- |
| **Gross Profit** | $40K | -- | -- | -- | -- | -- | -- | -- |
| Research & Development | $143K | $213K | $384K | $527K | $504K | $618K | $1.28M | $2.19M |
| Selling, General & Admin | $2.76M | $2.80M | $1.54M | $1.37M | $1.26M | $1.15M | $1.06M | -- |
| Total Operating Expenses | $2.90M | $3.01M | $1.93M | $1.90M | $1.76M | $1.77M | $2.34M | $3.20M |
| **Operating Income** | -$2.86M | -$3.01M | -$1.93M | -$1.90M | -$1.76M | -$1.77M | -$2.34M | -$3.20M |
| Interest Income | $37K | $47K | $79K | $39K | $69K | $72K | $36K | $49K |
| **Net Income** | -$2.82M | -$2.97M | -$1.85M | -$1.86M | -$1.69M | -$1.70M | -$2.30M | -$3.15M |
| Basic EPS | -$0.55 | -$0.74 | -$0.48 | -- | -$1.65 | -$1.22 | -$4.47 | -- |
| **Diluted EPS** | -$0.55 | -$0.74 | -$0.48 | -- | -$1.65 | -$1.66 | -$4.47 | -- |
| Basic Shares Outstanding | 5.1M | 4.0M | 3.9M | -- | 1.0M | 1.0M | 515.5K | -- |
| Diluted Shares Outstanding | 5.1M | 4.0M | 3.9M | -- | 1.0M | 1.0M | 515.5K | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $7.52M | $3.16M | -- | $6.24M | $10.80M | $530K |
| **Cash & Short-Term Investments** | $7.52M | $3.16M | -- | $6.24M | $10.80M | $530K |
| **Total Current Assets** | $7.86M | -- | -- | -- | $11.62M | $605K |
| Property, Plant & Equipment, Net | -- | -- | -- | -- | $0 | $0 |
| **Total Non-Current Assets** | $0 | -- | -- | -- | $0 | $0 |
| **Total Assets** | $7.86M | $3.53M | $7.98M | $6.94M | $11.62M | $605K |
| Accounts Payable | $461K | $808K | $866K | $497K | $515K | $104K |
| Short-Term Debt | -- | -- | -- | -- | $0 | $556K |
| **Total Current Liabilities** | -- | -- | -- | -- | $1.52M | $3.78M |
| **Total Non-Current Liabilities** | -- | -- | -- | -- | $0 | $0 |
| **Total Liabilities** | $1.64M | $1.97M | $1.62M | $923K | $1.52M | $3.78M |
| **Total Debt (incl. Leases)** | -- | -- | -- | -- | $0 | $556K |
| Common Stock | $266 | $25 | $26 | $77 | $833 | $0 |
| Retained Earnings | -$73.23M | -$65.68M | -$53.39M | -$45.59M | -$35.98M | -$28.08M |
| **Total Stockholders' Equity** | $6.22M | $1.56M | $6.36M | $6.02M | $10.11M | -$3.18M |
| Total Equity | $6.22M | $1.56M | $6.36M | $6.02M | $10.11M | -$3.18M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $4.82M | $4.41M | $6.95M | $7.52M | $4.66M | $6.48M | $9.72M | $3.16M |
| **Cash & Short-Term Investments** | $4.82M | $4.41M | $6.95M | $7.52M | $4.66M | $6.48M | $9.72M | $3.16M |
| Inventory | $825K | $150K | $93K | -- | -- | -- | -- | -- |
| **Total Current Assets** | $6.43M | $5.16M | -- | $7.86M | -- | -- | -- | -- |
| Property, Plant & Equipment, Net | $159K | $129K | -- | -- | -- | -- | -- | -- |
| **Total Non-Current Assets** | $205K | $165K | -- | $0 | -- | -- | -- | -- |
| **Total Assets** | $6.64M | $5.32M | $7.47M | $7.86M | $5.07M | $6.64M | $10.01M | $3.53M |
| Accounts Payable | $1.62M | $1.12M | $318K | $461K | $453K | $414K | $1.40M | $808K |
| **Total Liabilities** | $2.73M | $1.83M | $1.05M | $1.64M | $1.11M | $1.03M | $2.70M | $1.97M |
| Common Stock | $493 | $402 | $402 | $266 | $84 | $64 | $603 | $25 |
| Retained Earnings | -$80.87M | -$78.05M | -$75.08M | -$73.23M | -$71.37M | -$69.68M | -$67.98M | -$65.68M |
| **Total Stockholders' Equity** | $3.91M | $3.49M | $6.41M | $6.22M | $3.96M | $5.61M | $7.30M | $1.56M |
| Total Equity | $3.91M | $3.49M | $6.41M | $6.22M | $3.96M | $5.61M | $7.30M | $1.56M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$7.56M | -$12.29M | -$7.79M | -$9.61M | -$7.90M | -$3.24M |
| Depreciation & Amortization | -- | -- | -- | -- | $0 | $322 |
| Stock-Based Compensation | $144K | $658K | $522K | $930K | $1.91M | $0 |
| Change in Payables | -$388K | -$109K | $369K | -$19K | $411K | -$233K |
| **Operating Cash Flow** | -$7.80M | -$11.16M | -$6.41M | -$8.83M | -$5.69M | -$4.03M |
| Common Stock Issued | $12.17M | $6.89M | $7.61M | $4.28M | $15.39M | -- |
| **Financing Cash Flow** | $12.12M | $6.89M | $7.61M | $4.28M | $15.96M | $2.57M |
| **Net Change in Cash** | $4.36M | -$4.28M | $1.20M | -$4.56M | $10.27M | -$1.46M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$2.82M | -$2.97M | -$1.85M | -$1.86M | -$1.69M | -$1.70M | -$2.30M | -$3.15M |
| Stock-Based Compensation | $42K | $42K | $43K | $29K | $38K | $39K | $37K | $30K |
| Change in Inventory | -$676K | -$57K | -$93K | -- | -- | -- | -- | -- |
| Change in Payables | $444K | $783K | -$51K | -$84K | $53K | -$459K | $102K | -$98K |
| **Operating Cash Flow** | -$2.65M | -$2.42M | -$2.48M | -$1.37M | -$1.80M | -$2.69M | -$1.93M | -$2.91M |
| Common Stock Issued | -- | -- | -- | $4.19M | -$13K | -$548K | $8.54M | -$70K |
| **Financing Cash Flow** | $3.31M | -$323 | $1.90M | $4.19M | -$13K | -$548K | $8.49M | -$69K |
| **Net Change in Cash** | $610K | -$2.53M | -$577K | $2.86M | -$1.82M | -$3.24M | $6.56M | -$2.98M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -121.5% | -787.1% | -122.7% | -159.6% | -78.2% | -- |
| Return on Assets (ROA) | -96.1% | -347.7% | -97.7% | -138.4% | -68.0% | -534.6% |
| Current Ratio | -- | -- | -- | -- | 7.66x | 0.16x |
| Quick Ratio | -- | -- | -- | -- | 7.12x | 0.14x |
| Debt to Equity | -- | -- | -- | -- | 0.00x | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -243.2% | -239.9% | -110.8% | -121.5% | -223.4% | -184.0% | -156.9% | -787.1% |
| Return on Assets (ROA) | -143.1% | -157.3% | -95.1% | -96.1% | -174.5% | -155.5% | -114.5% | -347.7% |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
